JP2023517078A5 - - Google Patents

Info

Publication number
JP2023517078A5
JP2023517078A5 JP2022554294A JP2022554294A JP2023517078A5 JP 2023517078 A5 JP2023517078 A5 JP 2023517078A5 JP 2022554294 A JP2022554294 A JP 2022554294A JP 2022554294 A JP2022554294 A JP 2022554294A JP 2023517078 A5 JP2023517078 A5 JP 2023517078A5
Authority
JP
Japan
Application number
JP2022554294A
Other languages
Japanese (ja)
Other versions
JPWO2021183529A5 (https=
JP2023517078A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/021527 external-priority patent/WO2021183529A1/en
Publication of JP2023517078A publication Critical patent/JP2023517078A/ja
Publication of JPWO2021183529A5 publication Critical patent/JPWO2021183529A5/ja
Publication of JP2023517078A5 publication Critical patent/JP2023517078A5/ja
Pending legal-status Critical Current

Links

JP2022554294A 2020-03-11 2021-03-09 ツカチニブを用いてher2突然変異を有するがんを処置する方法 Pending JP2023517078A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988312P 2020-03-11 2020-03-11
US62/988,312 2020-03-11
PCT/US2021/021527 WO2021183529A1 (en) 2020-03-11 2021-03-09 Methods of treating her2 mutant cancers with tucatinib

Publications (3)

Publication Number Publication Date
JP2023517078A JP2023517078A (ja) 2023-04-21
JPWO2021183529A5 JPWO2021183529A5 (https=) 2024-03-19
JP2023517078A5 true JP2023517078A5 (https=) 2024-03-19

Family

ID=75278374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554294A Pending JP2023517078A (ja) 2020-03-11 2021-03-09 ツカチニブを用いてher2突然変異を有するがんを処置する方法

Country Status (9)

Country Link
US (1) US20230136203A1 (https=)
EP (1) EP4118237A1 (https=)
JP (1) JP2023517078A (https=)
KR (1) KR20220152287A (https=)
CN (1) CN115698338A (https=)
CA (1) CA3174986A1 (https=)
IL (1) IL296227A (https=)
MX (1) MX2022011160A (https=)
WO (1) WO2021183529A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060407A1 (en) 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
MX2022004699A (es) * 2019-10-21 2022-08-08 Seagen Inc Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
US20210239702A1 (en) * 2018-06-14 2021-08-05 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies

Similar Documents

Publication Publication Date Title
JP2022553041A5 (https=)
JP2023517078A5 (https=)
CN305530850S (https=)
CN305680976S (https=)
CN305569511S (https=)
CN305547947S (https=)
CN305536891S (https=)
CN305535517S (https=)
CN305535494S (https=)
CN305546715S (https=)
CN305534937S (https=)
CN305532381S (https=)
CN305531782S (https=)
CN305545846S (https=)
CN305531113S (https=)
CN305527936S (https=)
CN305527241S (https=)
CN305526901S (https=)
CN305716288S (https=)
CN305713288S (https=)
CN305713189S (https=)
CN305712069S (https=)
CN305710080S (https=)
CN305708672S (https=)
CN305566084S (https=)